Atopic Dermatitis

Clinicians James Q. Del Rosso, DO; Raj Chovatiya, MD, PhD; and Lisa Swanson, MD, PhD, review the study, “Rapid Pruritus Reduction With Ruxolitinib Cream in Patients With Atopic Dermatitis."

Experts discuss prospective therapies on the horizon for atopic dermatitis (AD).

Children of mothers who took more than 5 courses of antibiotics during pregnancy were at the highest risk.

Experts offer their clinical experience on preventing patient withdrawal and breaking the atopic dermatitis (AD) disease cycle.

Adam Friedman, MD, FAAD, and Andrew Alexis, MD, MPH, discuss disparities in atopic dermatitis and the ways these can be addressed with teledermatology.

In a Dermatology Times DermView custom video series, Shawn Kwatra, MD, and Peter Lio, MD, discuss the topical treatment landscape of atopic dermatitis.

Pediatricians are often the first to diagnose and manage pediatric atopic dermatitis, and Larry Eichenfield, MD, led a team to develop a tool to help them.

Peter Lio, MD also explained why he considers it a bad day when he does not learn something new about this disease.

AB-101a is a new topical treatment being investigated for mild, moderate, and severe atopic dermatitis and its immune system component.

Peter Lio, MD, FAAD, discusses how body surface area of atopic dermatitis (AD) affects topical treatment options.

Shawn Kwatra, MD, offers important considerations for providers when utilizing topical therapies for atopic dermatitis (AD).

The TRuE-AD3 study met its primary endpoint of IGA-TS improvement from baseline at week 8.

Alphyn Biologics announced positive results from their Phase 2a trial of AB-101a will lead to a multinational Phase 2b trial soon.

Dupilumab self-injection has been available to patients in Japan since May 2019.

Examining the genes and signaling pathways of development of atopic dermatitis and tooth agenesis reveals possible link between the two diseases.

Findings indicate no rebound effect when participants discontinue dupilumab.

Pediatric patients with moderate to severe eczema demonstrated an increased risk of experiencing the food allergy.

Experts discuss the history and evolving landscape of topical steroids as therapy for atopic dermatitis (AD).

Peter Lio, MD, FAAD, and Shawn Kwatra, MD, discuss janus kinase (JAK) inhibitors and their recent use in the treatment of atopic dermatitis (AD).

The ongoing Canadian wildfires are causing poor air quality in the US, which will likely result in more patients seeking help for skin conditions.

Sanofi’s investigational anti-OX40-ligand monoclonal antibody showed statistically significant improvement in signs and symptoms of AD in adults.

Experts discuss the symptoms of atopic dermatitis (AD) and how disease severity may impact symptoms.

Shawn Kwatra, MD, and Peter Lio, MD, FAAD, discuss the burden of atopic dermatitis (AD) and how it may affect pediatric or adult patients.

A poster presented at the SDPA Annual Summer Dermatology Conference revealed the abrocitinib did not have a significant impact on adolescent immune responses to Tdap vaccination.

Four clinicians discuss the widening landscape of systemic therapies for patients with atopic dermatitis.